在类风湿性关节炎中实施治疗目标的挑战:来自巴西风湿病学家的观点
Adriana Maria Kakehasi1, Angela Luzia Branco Pinto Duarte2, Claiton Viegas Brenol3
1Universidade Federal de Minas Gerais, Avenida Alfredo Balena, 190, Belo Horizonte, Brazil. amkakehasi@gmail.com.
Advances in rheumatology (London, England)
|August 26, 2024
概括
风湿病学家面临的挑战实施治疗到目标 (T2T) 对于类风湿性关节炎 (RA),包括不一致的措施和患者不良坚持. 改善沟通和共享决策对于更好的RA管理和患者结果至关重要.
科学领域:
- 类风湿病学 类风湿病学
- 临床实践 临床实践
- 提高质量 提高质量
背景情况:
- 在类风湿性关节炎 (RA) 管理中,建议采用治疗到目标 (T2T) 方法,以实现缓解.
- 尽管有好处,但T2T在临床实践中的实施仍然不够理想.
- 埃弗雷斯特计划旨在加强RA护理中T2T战略的采用.
研究的目的:
- 评估巴西风湿病学家在T2T战略实施中的障碍和知识差距.
- 评估使用T2T方法管理RA患者的当前做法和挑战.
主要方法:
- 在2022年6月至9月期间,在巴西的风湿病学家中进行了一项在线调查.
- 该调查使用多选题来收集有关感知挑战和知识差距的数据.
- 166名风湿病学家参加了这次活动,其中一半以上的风湿病学家有超过21年的经验.
主要成果:
- 矛盾的疾病活动测量是最重要的感知挑战 (60%).
- 缺乏治疗坚持 (75%) 和患者报告结果不一致 (59%) 是主要障碍.
- 在评估患者健康素养方面发现了重大知识和技能差距 (54%的知识,43%的技能).
- 使用支持工具,如问卷和检查清单是不常见的.
结论:
- 需要改进的实践策略来加强医疗保健提供者和RA患者之间的沟通.
- 加强知情,协作决策对于优化RA患者护理至关重要.
- 解决已识别的障碍可以促进在RA管理中更有效地实施T2T.
相关概念视频
01:26Targets for Drug Action: Overview
6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
01:29Inflammatory Bowel Disease IV: Pharmacological Management
123
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
123
01:28Drug Therapy
40
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
40
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
145
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
145